Financial Wealth Daily

Nvidia’s AI chip demand to face limited impact from potential production delay, analysts say

(Reuters) – Worries over a delay in the launch of Nvidia’s upcoming artificial-intelligence chips may be exaggerated, analysts said, as they do not expect the setback to have a big impact on the chip giant’s revenue or demand. According to media reports, Nvidia’s Blackwell chips may face delays of three months or more due to…

Read More

Coinbase expects US to be crypto-friendly irrespective of election outcome

By Niket Nishant and Manya Saini (Reuters) – The next U.S. administration will be “constructive” on crypto regardless of which party wins, Coinbase CEO Brian Armstrong said late on Thursday, underscoring the industry’s growing political influence ahead of the November election. The highly volatile crypto sector is seen as a risky fringe industry and has…

Read More

U.S. sues TikTok over ‘massive-scale’ privacy violations of kids under 13

By David Shepardson WASHINGTON (Reuters) – The U.S. Justice Department filed a lawsuit Friday against TikTok and parent company ByteDance for failing to protect children’s privacy on the social media app. The government said TikTok violated the Children’s Online Privacy Protection Act that requires services aimed at children to obtain parental consent to collect personal…

Read More

Dollar hits four-month low as weak US jobs data boosts rate cut bets

By Karen Brettell NEW YORK (Reuters) -The U.S. dollar dropped to a four-month low on Friday after a weaker-than-expected employment report for July raised expectations that the Federal Reserve will cut interest rates by 50 basis points in September as the economy sours. Employers added 114,000 jobs, below expectations for an increase of 175,000. The…

Read More

Lilly CEO says weight-loss drug shortage to end ‘very soon’, Bloomberg News reports

(Reuters) – U.S. drugmaker Eli Lilly expects its blockbuster weight-loss drug to officially come out of shortage in the United States in coming days, Bloomberg News reported on Thursday, citing an interview with the company’s CEO, David Ricks. Lilly’s drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management, will cease to be…

Read More